On December 23, 2020 BioInvent International AB (OMXS: BINV ), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, reported that Pfizer Inc. ("Pfizer") (NYSE: PFE) has selected antibodies directed at a previously-selected target under the companies’ cancer immunotherapy research collaboration and license agreement (Press release, BioInvent, DEC 23, 2020, View Source [SID1234573216]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement, into which the companies entered in December 2016, covers developing antibodies from BioInvent’s proprietary F.I.R.S.TTM drug discovery platform targeting tumor-associated myeloid cells.

The selection of these antibodies triggers a payment from Pfizer to BioInvent of $3,000,000. BioInvent is eligible for further milestone payments from development of these antibodies and potential selection and development of further antibodies directed at the same target.

BioInvent’s CEO Martin Welschof said: "Pfizer’s selection of antibodies under our agreement is a great demonstration of the actionable leads generated by our drug discovery technology platform. We are very pleased with how our partnership is progressing and look forward to further strengthening our collaboration. Our F.I.R.S.TTM platform is a patient-centric approach, drawing on our high-quality n-CoDeR antibody library to produce promising drug candidates, and we believe this partnership is an important validation of this technology."